Newswise - STONY BROOK, N.Y., January 6, 2012 - For children and adolescents with HIV infection, the recent
Food and Drug Administration (FDA) approval of the use of raltegravir, an antiretroviral drug that slows the spread of HIV infection,
offers a new weapon to treat HIV infection in children. So says Sharon Nachman, M.D., Associate Dean for Research and Professor of
Pediatrics, Stony Brook University School of Medicine, and the Principal Investigator and Study Chair of a national multicenter
clinical trial that studied the safety and efficacy of raltegravir in HIV-infected children and adolescents.
The FDA approved raltegravir for use with other antiretroviral drugs for the treatment of HIV infection in children and
adolescents ages 2 to 18 years on December 21. Approved for use in adults in 2007, raltegravir is part of a class of medications called
HIV integrase inhibitors.
In the clinical trial, sponsored by the National Institute of Health's National Institute of Allergy and Infectious
Diseases, all of the 96 patients enrolled had previously been treated with a regimen of other HIV medications before raltegravir.
After being treated for 24 weeks with raltegravir, 53 percent of the patients had an undetectable amount of HIV in their blood.
"Raltegravir is an important new option for children with HIV. The trial shows it has an excellent efficacy profile in
children with HIV who have failed other regimens and is also effective against the virus regardless where the child lives around the
word," says Dr. Nachman. "The data also shows no significant toxicities or interactions with other HIV medications."
The formulation of raltegravir in children is a pill that can be taken twice daily, with or without food. For younger
patients, there is a chewable form. Dr. Nachman points out that in addition to the drug being an important new option for pediatric
patients, the formulations available are more convenient and may help increase patient compliance.
The FDA indicates that the most commonly reported severe, treatment-related side effects in patients taking raltegravir
include insomnia and headache. The frequency of these side effects is similar in adults and children.
Dr. Nachman says that the study of the use of raltegravir to treat HIV in children and adolescents will continue. Each
child enrolled will be followed for five years. During that period, Dr. Nachman and colleagues will continue to evaluate efficacy and
any long-term complications of the medicine in the patient population.
The study provides the only pediatric data on the use of raltegravir in patients ages 2 to 18 years. Patients are enrolled
through Stony Brook and other study locations nationwide. Dr. Nachman says that one of the next steps to advance the study is to evaluate
a novel baby formulation.
About Stony Brook University School of Medicine
Established in 1971, the Stony Brook University School of Medicine includes 25 academic departments. The three missions of the School
are to advance the understanding of the origins of human health and disease, train the next generation of committed, curious and
highly capable physicians, and deliver word-class compassionate healthcare. As a member of the Association of American Medical
Colleges (AAMC) and a Liaison Committee on Medical Education (LCME) accredited medical school, Stony Brook is one of the
foremost institutes of higher medical education in the country. Each year the School trains nearly 500 medical students
and over 480 medical residents and fellows. Faculty research includes National Institutes of Health-sponsored programs
in neurological diseases, cancer, cardiovascular disorders, biomedical imaging, regenerative medicine, infectious
diseases, and many other topics. To learn more, visit www.stonybrookmedicalcenter.org/som .